May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Correlations Between Changes in OCT Central Retinal Thickness and Visual Acuity in the PrONTO Study
X. Sun; G. A. Lalwani; A. E. Fung; S. Michels; S. R. Dubovy; C. A. Puliafito; W. J. Feuer; P. J. Rosenfeld
Author Affiliations & Notes
  • X. Sun
    Ophthalmology, Bascom Palmer Eye Institute, SOM, University of Miami.Eye Research Institute of Shanghai Jiao Tong University, Miami, Shanghai, Florida
  • G. A. Lalwani
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • A. E. Fung
    California Pacific Medical Center, Pacific Eye Associates, San Francisco, California
  • S. Michels
    Ophthalmology, University of Vienna, Vienna, Austria
  • S. R. Dubovy
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Maimi, Florida
  • C. A. Puliafito
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida
  • W. J. Feuer
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • P. J. Rosenfeld
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • Footnotes
    Commercial Relationships X. Sun, None; G.A. Lalwani, None; A.E. Fung, Genentech, F; Genentech, Santen, C; Genentech, Santen, R; S. Michels, Novartis, R; S.R. Dubovy, None; C.A. Puliafito, Zeiss Meditec, F; Genentech, Zeiss Meditec, C; Zeiss Meditec, P; Genentech, R; W.J. Feuer, None; P.J. Rosenfeld, Genentech, Eyetech, Alcon Laboratories, F; Genentech, Eyetech Pharmaceuticals, Novartis Ophthalmics, Allergan, Protein Design Labs, Tanox, Genaera, Jerini AG, Quark Inc, Athenagen, C; Genentech, Eyetech, and Novartis Ophthalmics, Zeiss Meditec, R.
  • Footnotes
    Support Genentech, an unrestricted grant to the University of Miami from Research to Prevent Blindness, and the China Scholarship Council.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4578. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Correlations Between Changes in OCT Central Retinal Thickness and Visual Acuity in the PrONTO Study
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      X. Sun, G. A. Lalwani, A. E. Fung, S. Michels, S. R. Dubovy, C. A. Puliafito, W. J. Feuer, P. J. Rosenfeld; Correlations Between Changes in OCT Central Retinal Thickness and Visual Acuity in the PrONTO Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4578.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: In the PrONTO study, patients were treated with 3 consecutive monthly injections of Lucentis (ranibizumab) followed by retreatment as needed based on an OCT-guided variable dosing regimen. Overall, mean visual acuity improved by 9.3 letters at 1 year with 35% of patients gaining at least 15 letters. This improvement was achieved with an average of only 5.6 injections over the first year. We analyzed the data to determine if the decrease in OCT central retinal thickness measurements correlated with the improvements in visual acuity during the first year.

Methods:: Visual acuity assessments and OCT central retinal thickness measurements were performed at baseline and monthly thereafter. Visual acuity letter scores were determined using a standard protocol refraction with the ETDRS chart at 2 meters. The central 1 mm OCT central retinal thickness measurements were obtained from the macular thickness maps calculated from the 6 low resolution diagonal scans once appropriate boundaries were confirmed. The influence of OCT central retinal thickness changes on visual acuity changes from baseline were assessed with both Pearson correlation and Spearman non-parametric correlation analyses.

Results:: At one month, there were no statistically significant correlations between the decrease in central retinal thickness and the improvement in visual acuity (Pearson, r=0.25, P=0.12; Spearman, r=0.23, P=0.15). However, after the first month, statistically significant correlations were observed between the decrease in central retinal thickness at 1 month and the improvements in visual acuity seen at 2 months (Pearson, r=0.57, P<0.001; Spearman, r=0.47, P=0.002), 3 months (Pearson, r=0.51, P=0.001; Spearman, r=0.36, P=0.021), and every subsequent month through Month 12 (Pearson, r=0.37, P=0.019; Spearman, r=0.38, P=0.015).

Conclusions:: The initial OCT response to Lucentis therapy appears to be correlated with future visual acuity improvements. Additional correlation analyses will be presented through 24 months of the study.

Clinical Trial:: www.clinicaltrials.gov NCT00344227

Keywords: age-related macular degeneration • choroid: neovascularization • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept